Market closedNon-fractional
AADi Bioscience/AADI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About AADi Bioscience
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
Ticker
AADI
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Pacific Palisades, United States
Employees
75
Website
aadibio.com
AADi Bioscience Metrics
BasicAdvanced
$40M
Market cap
-
P/E ratio
-$2.55
EPS
0.35
Beta
-
Dividend rate
Price and volume
Market cap
$40M
Beta
0.35
Financial strength
Current ratio
5.161
Quick ratio
4.69
Long term debt to equity
0.816
Total debt to equity
1.286
Interest coverage (TTM)
-323.03%
Management effectiveness
Return on assets (TTM)
-33.11%
Return on equity (TTM)
-58.22%
Valuation
Price to revenue (TTM)
1.82
Price to book
0.43
Price to tangible book (TTM)
0.43
Price to free cash flow (TTM)
-0.707
Growth
Revenue change (TTM)
26.97%
Earnings per share change (TTM)
-0.94%
3-year revenue growth (CAGR)
17.78%
3-year earnings per share growth (CAGR)
-22.21%
What the Analysts think about AADi Bioscience
Analyst Ratings
Majority rating from 5 analysts.
AADi Bioscience Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$5.3M
-15.87%
Net income
-$18M
12.35%
Profit margin
-343.39%
33.54%
AADi Bioscience Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.67
-$0.60
-$0.60
-$0.68
-
Expected
-$0.62
-$0.72
-$0.65
-$0.64
-$0.69
Surprise
7.72%
-17.13%
-7.41%
5.84%
-
AADi Bioscience News
AllArticlesVideos
Aadi Bioscience to Participate in the Jefferies Healthcare Conference
PRNewsWire·2 months ago
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting
PRNewsWire·2 months ago
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update
PRNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AADi Bioscience stock?
AADi Bioscience (AADI) has a market cap of $40M as of July 27, 2024.
What is the P/E ratio for AADi Bioscience stock?
The price to earnings (P/E) ratio for AADi Bioscience (AADI) stock is 0 as of July 27, 2024.
Does AADi Bioscience stock pay dividends?
No, AADi Bioscience (AADI) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next AADi Bioscience dividend payment date?
AADi Bioscience (AADI) stock does not pay dividends to its shareholders.
What is the beta indicator for AADi Bioscience?
AADi Bioscience (AADI) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell AADi Bioscience stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.